Published in Blood Weekly, July 18th, 2002
HH is a genetically inherited disease that results in excess storage of iron, principally in the liver and bone joints. Nanogen has had an exclusive license to the '425 patent from Billups-Rothenberg, Inc., and Dr. Barry E. Rothenberg since 1998.
The '425 patent addresses identification and detection of mutations in the HFE gene, which is critical to diagnosing HH. Under this patent, Nanogen has exclusive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.